Evaluating Clinic Claims

What this page is for

Some clinics advertise psychedelic therapy, most often with psilocybin. This page helps you read those descriptions. It does not list, rate or recommend clinics, and it does not tell anyone to start, stop or change a medicine. Talk with your own prescriber about that: talking with a health professional.

Evidence labels: mixed, insufficient evidence and marketing claim (a statement made to attract clients, not shown by the sources read). Psilocybin therapy is still investigational and not approved for general use, so a clinic that sounds sure about results deserves a closer look.

Start with what is actually being offered

Clinics use similar words for very different things. Ask which of these it is:

• A research study with a written plan, screening and trained monitors.
• A state-licensed service, in a place that has created one, such as Oregon's psilocybin program.
• A private service that is neither of those. Its own description of safety is a marketing claim unless you can check it.

What studies of clinic advertising found

These studies looked at websites, not at the care itself, so they show how clinics talk, not whether treatment was good or bad.

• Ontario, Canada, 10 clinic websites. They advertised psychedelics for 47 medical conditions, most commonly depression. Only 2 of 10 described risks, and the cited evidence was of low to moderate quality. [1]

This covers one region and one time. It does not show every clinic behaves this way.

A claims checklist

Questions to ask, and what a good answer looks like, based on the findings above.

1. What exactly is offered, and is it approved for this use? A clear answer names the substance and says plainly whether it is part of a trial, a licensed program or neither. Unclear answers are a warning sign.
2. What evidence supports it for my condition? A claim for "47 conditions" is not the same as trial evidence for one. See how to read a psychedelic trial.
3. Are risks stated? A clinic that says a treatment is "nonaddictive" or "safe" with no discussion of risks is making a marketing claim.
4. Who supervises, and where? Check who is present during and after treatment, and what monitoring is described. Compare with clinical monitoring.
5. Who is involved, and are credentials stated? See therapist and practitioner qualifications.
6. What screening comes first? In an Oregon study of licensed psilocybin service centers, callers posing as people with depression reached 15 of 22 centers, none of which allowed unsupervised use or immediate dosing without psychiatric assessment. [2] That is one state and one model, not a standard everywhere. See screening and eligibility.
7. What does it say about aftercare and problems? See follow-up and ongoing care.

Statements that deserve a second look

• "Proven," "cure," or "works for everything": no source we read supports this.
• Therapy added on top of a psychedelic: FDA says the contribution of the psychotherapy part to any benefit has not been characterized. [3]
• Pressure to decide quickly, or to stop other treatment, which is a matter for your prescriber.

If you have had a problem

Safety reports and complaint routes are on vulnerability, suggestibility and misconduct. In the US, call 988 for emotional crisis or 911 for an emergency.